Barclays Issues Positive Forecast for Envista (NYSE:NVST) Stock Price

Envista (NYSE:NVST) had its price target lifted by research analysts at Barclays from $24.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 14.79% from the company’s current price.

A number of other equities analysts have also commented on the stock. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 26th. Robert W. Baird set a $30.00 target price on Envista in a report on Friday. Evercore ISI set a $32.00 price target on Envista and gave the stock an “outperform” rating in a research report on Friday. Stifel Nicolaus set a $31.00 price target on Envista in a report on Friday. Finally, Piper Sandler reissued a “neutral” rating and issued a $25.00 price objective (up previously from $21.00) on shares of Envista in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.43.

Envista Trading Down 1.8%

Shares of NVST opened at $29.62 on Wednesday. The stock has a 50 day simple moving average of $23.17 and a 200-day simple moving average of $21.37. The company has a current ratio of 2.38, a quick ratio of 2.04 and a debt-to-equity ratio of 0.47. The stock has a market cap of $4.87 billion, a PE ratio of 105.96, a PEG ratio of 2.01 and a beta of 1.01. Envista has a 1 year low of $14.22 and a 1 year high of $30.42.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. The firm had revenue of $750.60 million for the quarter, compared to analysts’ expectations of $680.26 million. Envista had a return on equity of 6.54% and a net margin of 1.73%.The business’s revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, sell-side analysts predict that Envista will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of large investors have recently made changes to their positions in NVST. Royal Bank of Canada grew its holdings in Envista by 26.6% in the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock valued at $401,000 after buying an additional 4,885 shares in the last quarter. Millennium Management LLC increased its position in Envista by 218.6% during the first quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock worth $6,627,000 after acquiring an additional 263,442 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Envista by 39.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock valued at $10,859,000 after purchasing an additional 177,630 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Envista by 15.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock worth $9,821,000 after purchasing an additional 76,246 shares in the last quarter. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Envista by 11.3% during the second quarter. KLP Kapitalforvaltning AS now owns 36,400 shares of the company’s stock worth $711,000 after purchasing an additional 3,700 shares during the period.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.